Twitter chief executive Jack Dorsey has appeared on a podcast with a controversial fitness personality who has promoted scientifically disproven claims that vaccinations cause autism. Host Ben Greenfield – who tweeted in February that "vaccines do indeed cause autism" – thanked Mr Dorsey for an "epic podcast". The Twitter boss responded: "Great conversation and appreciate all you do to simplify the mountains of research focused on increasing one's healthspan! We'll tell you what's true. You can form your own view. His appearance comes as other tech firms like Facebook and Pinterest are cracking down on anti-vaccine content on their platforms. However, Twitter claimed Mr Dorsey was unaware of the host's controversial opinions. A Twitter spokesperson told The Independent that Mr Dorsey did not know about Mr Greenfield's views on vaccinations and that his podcast appearance was not an endorsement of those beliefs. Sheen fought a legal battle against ex-wife Denise Richards to try and ...
In 1983, the IBM PC XT debuted with 128K of RAM and a 10MB hard disk. In that same year, the first mobile phone debuted weighing about 2.5 pounds and with a $4,000 price tag. Fast forward to today and the average person unlocks their smartphone 76-80 times a day and relies on it for every aspect of their lives. These amazing pieces of hardware are millions of times more capable than all of NASA's computing power in the 1960s. Now that we have a supercomputer that never leaves people's sides, maybe it's time that we do some more innovation and see how that device can be used for "mobile health".
Recent American news events range from horrifying to dystopian, but reading the applications of our fast.ai I was blown away by how many bright, creative, resourceful folks from all over the world are applying deep learning to tackle a variety of meaningful and interesting problems. Their passions range from ending illegal logging, diagnosing malaria in rural Uganda, translating Japanese manga, reducing farmer suicides in India via better loans, making Nigerian fashion recommendations, monitoring patients with Parkinson's disease, and more. Our mission at fast.ai is to make deep learning accessible to people from varied backgrounds outside of elite institutions, who are tackling problems in meaningful but low-resource areas, far from mainstream deep learning research. Our group of selected fellows for Deep Learning Part 2 includes people from Nigeria, Ivory Coast, South Africa, Pakistan, Bangladesh, India, Singapore, Israel, Canada, Spain, Germany, France, Poland, Russia, and Turkey.
IBM Watson Health has formed a medical imaging collaborative with more than 15 leading healthcare organizations. The goal: To take on some of the most deadly diseases. The collaborative, which includes health systems, academic medical centers, ambulatory radiology providers and imaging technology companies, aims to help doctors address breast, lung, and other cancers; diabetes; eye health; brain disease; and heart disease and related conditions, such as stroke. Watson will mine insights from what IBM calls previously invisible unstructured imaging data and combine it with a broad variety of data from other sources, such as data from electronic health records, radiology and pathology reports, lab results, doctors' progress notes, medical journals, clinical care guidelines and published outcomes studies. As the work of the collaborative evolves, Watson's rationale and insights will evolve, informed by the latest combined thinking of the participating organizations.
An artist's impression of the European Space Agency's Rosetta probe, which aims to be the first to land on a comet. Several research groups, including a team led by geneticist Erika Sasaki and stem-cell biologist Hideyuki Okano at Keio University in Tokyo, hope to create transgenic primates with immune-system deficiencies or brain disorders. This could raise ethical concerns, but might bring us closer to therapies that are relevant to humans (mice can be poor models for such disorders). The work will probably make use of a gene-editing method called CRISPR, which saw rapid take-up last year. The European Space Agency's Rosetta spacecraft could become the first mission to land a probe on a comet.